Baytril Piglet Doser 0.5% Oral Solution
A |
|
|
|
Baytril Piglet Doser |
As per C. Eyett-Burton 21 Aug ‘07 |
August 2007 |
Page 5 of 5 |
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Baytril Piglet Doser
0.5% Oral Solution
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
2.1 |
Active Constituents |
mg per ml |
|
Enrofloxacin |
5.0 |
|
|
|
2.2 |
Relevant Constituents of the Excipients |
|
|
Benzyl Alcohol |
14.0 |
For full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM
Oral solution.
Clear aqueous solution
4. CLINICAL PARTICULARS
4.1 Target species
Piglets
4.2 Indications for use, specifying the target species
The product is for use in the treatment of diseases of the respiratory and alimentary tracts of bacterial or mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis), and multifactorial diseases such as atrophic rhinitis and enzootic pneumonia, where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
4.3 Contraindications
Should not be used for prophylaxis.
4.4 Special warnings for each target species
None known
4.5 Special precautions for use
i) Special precautions for use in animals
Official and local antimicrobial policies should be taken into account when the product is used.
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.
Whenever possible, fluoroquinolones should only be used based on susceptibility testing.
Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
ii) Special precautions to be taken by the person administering the medicinal product to animals
Wear impervious gloves when handling the product.
Wash any splashes from skin or eyes immediately with water.
Wash hands and exposed skin after use.
Do not eat, drink or smoke while using the product.
iii) Other precautions
None.
4.6 Adverse reactions (frequency and seriousness)
None known
4.7 Use during pregnancy, lactation or lay
Not applicable – this product is only indicated for piglets
4.8 Interaction with other medicinal products and other forms of interaction
None known.
4.9 Amount(s) to be administered and administration route
Dose rate is 1.5 – 5 mg enrofloxacin/kg bodyweight daily.
The contents of Baytril Piglet Doser are administered orally using the dosing pump. 1 pump stroke delivers 1 ml.
For piglets up to 3 kg bodyweight – 1 ml once daily for 3 to 5 days
For piglets 3 kg up to 10 kg bodyweight – 3 ml once daily for 3 to 5 days
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Do not exceed the recommended dose. In accidental overdose there is no antidote and treatment should be symptomatic.
4.11 Withdrawal period(s)
Piglets: Meat: 10 days
5. PHARMACOLOGICAL PROPERTIES
Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinoline group of antibiotics.
ATC Vet Code: QJ01MA90
5.1 Pharmacodynamics
It is bactericidal in action with activity against Gram positive and Gram negative bacteria and mycoplasmas. The mechanism of action of the quinolones is unique among antimicrobials – they act primarily to inhibit bacterial DNA gyrase, an enzyme responsible for controlling the supercoiling of bacterial DNA during replication. Resealing of the double standard helix is inhibited resulting in irreversible degradation of the chromosomal DNA. The fluoroquinolones also possess activity against bacteria in the stationary phase by an alteration of the permeability of the outer membrane phospholipid cell wall.
5.2 Pharmacokinetics
The pharmacokinetics of enrofloxacin are such that oral and parenteral administration leads to similar serum levels. Enrofloxacin possesses a high distribution volume. Tissue levels 2-3 times higher than that found in the serum have been demonstrated in laboratory animals and target species. Organs in which high levels can be expected are the lungs, liver, kidney, bone and lymphatic system. Enrofloxacin also distributes into the cerebrospinal fluid, the aqueous humour and the foetus in pregnant animals.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Potassium hydroxide
Benzyl alcohol
Hypromellose
Water purified
6.2 Incompatibilities
None known.
6.3 Shelf-life
-
Shelf-life of the product as packaged for sale:
3 years
Shelf-life after first opening the container:
Following withdrawal of the first dose, use the product within 28 days. Discard unused material.
6.4 Special precautions for storage
Do not store above 25C.
6.5 Nature and composition of immediate packaging
-
Container Material:
High density polyethylene bottles.
Container Closure:
Polypropylene screw cap.
Container Colour:
White.
Container Volumes:
100 ml.
Dosing Device:
Polypropylene/polyethylene/stainless steel pump dispensing 1ml
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate
Any unused product or waste material should be disposed of in accordance with national requirements.
7. MARKETING AUTHORISATION HOLDER
-
UK Only:
IE Only:
Bayer plc,
Animal Health Division,
Bayer House,
Strawberry Hill,
Newbury,
Berkshire RG14 1JA
Bayer Limited,
Animal Health Division,
Chapel Lane,
Swords,
Co. Dublin
8. MARKETING AUTHORISATION NUMBER(S)
-
UK Only:
IE Only:
Vm 00010/4079
VPA 10021/4/1
9. DATE OF FIRST AUTHORISATION
-
UK Only:
IE Only:
11 November 1993
01 October 1988
9.1 Last Renewal of the Authorisation
-
UK Only:
IE Only:
11 November 2003
01 October 2003
10. DATE OF REVISION OF THE TEXT
-
UK Only:
IE Only:
21 September 2006
12 January 2007
PROHIBITION OF SALE, SUPPLY AND/OR USE